
Zetagen Highlights Phase 2a Findings for ZetaMet™ in Patients with Lytic Bone Lesions at ASCO
Zetagen Therapeutics Reports Promising Phase 2a Results for Investigational ZetaMet™ in Metastatic Breast Cancer Patients With Lytic Bone Lesions Zetagen Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies…












